Market closedADR
argenx SE/$ARGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Ticker
$ARGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,599
Website
argenx SE Metrics
BasicAdvanced
$36B
46.31
$12.78
0.20
-
Price and volume
Market cap
$36B
Beta
0.2
52-week high
$650.79
52-week low
$562.96
Financial strength
Current ratio
7.289
Quick ratio
6.401
Long term debt to equity
0.591
Total debt to equity
0.71
Interest coverage (TTM)
-5.69%
Management effectiveness
Return on assets (TTM)
-0.16%
Return on equity (TTM)
17.36%
Valuation
Price to earnings (TTM)
46.312
Price to revenue (TTM)
15.758
Price to book
5.95
Price to tangible book (TTM)
6.15
Price to free cash flow (TTM)
-234.538
Growth
Revenue change (TTM)
77.52%
Earnings per share change (TTM)
-347.62%
3-year revenue growth (CAGR)
62.15%
3-year earnings per share growth (CAGR)
16.93%
argenx SE News
AllArticlesVideos
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
GlobeNewsWire·4 weeks ago
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of $36B as of April 02, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 46.31 as of April 02, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of April 02, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.